A Case Report
[Posted 17/Nov/2026]
AUDIENCE: Emergency Medicine, Endocrinology, Internal Medicine
KEY FINDINGS: Long-term PPI use may contribute to impaired calcium homeostasis through hypomagnesemia and reduced PTH secretion or responsiveness. Clinicians should consider electrolyte disturbances in patients presenting with unexplained muscle spasms, paresthesia or QTc prolongation.
BACKGROUND: Long-term proton pump inhibitor (PPI) therapy has been associated with mineral metabolism disturbances, particularly hypomagnesemia, which can interfere with calcium regulation. This case highlights a rare but serious presentation of symptomatic hypocalcemia in a patient taking pantoprazole for several years. Springer Nature Link
DETAILS: A 54-year-old woman presented with progressive weakness, tingling sensations and painful involuntary muscle contractions. Examination revealed bilateral carpopedal spasms and positive Trousseau’s and Chvostek’s signs. ECG showed QTc prolongation. Laboratory investigations revealed severe hypocalcemia, with total calcium of 5.2 mg/dL and ionized calcium of 0.74 mmol/L. She also had mild hypomagnesemia (1.5 mg/dL), vitamin D insufficiency (18 ng/mL) and an inappropriately low parathyroid hormone level (13 pg/mL).
The patient had been self-administering pantoprazole 40 mg daily for approximately four years without regular medical reassessment. Treatment included discontinuation of pantoprazole, intravenous calcium gluconate under cardiac monitoring, magnesium and vitamin D supplementation, followed by oral calcium therapy. Neuromuscular symptoms improved within 24 hours of treatment. At one-month follow-up, the patient remained asymptomatic, with normalized calcium and magnesium levels and improved vitamin D status.
Important limitation: This single case cannot establish that pantoprazole directly caused hypocalcemia. Vitamin D insufficiency and impaired PTH response may also have contributed.
Copyright © Skyscape. All rights reserved.
Source: Khaneghahi, A., Zamani, S., Akbari, M., et al. evere symptomatic hypocalcemia with neuromuscular hyperexcitability associated with long-term pantoprazole use: a case report. International Journal of Emergency Medicine. 2026; 19:261. Published: October 6, 2026. DOI: 10.1186/s12245-026-01398-5.
KEY FINDINGS: The change from PCOS to PMOS reflects a broader understanding of the condition and its implications beyond ovarian function. The review identifies several clinically relevant considerations:
BACKGROUND: PMOS affects an estimated 10%–13% of women of reproductive age and remains underdiagnosed. Historically viewed mainly as a reproductive condition, it is now recognized as a complex endocrine and metabolic disorder with reproductive, psychological, dermatological and cardiometabolic consequences. The change in nomenclature reflects a broader understanding of the condition. The term PCOS can be misleading because the ovarian appearance typically involves arrested follicles rather than an increased number of pathological ovarian cysts. The updated terminology is intended to better represent the condition's underlying biology and its effects beyond the ovaries.
DETAILS: Insulin resistance as the central mechanism Insulin resistance is a defining feature of PMOS and is reported in 75% of lean women and 95% of overweight women when measured using euglycemic–hyperinsulinemic clamps. Unlike insulin resistance associated primarily with obesity, the condition appears to involve an intrinsic, tissue-specific defect that can occur independently of excess adiposity. Compensatory hyperinsulinemia contributes to increased ovarian and adrenal androgen production, reduced hepatic sex hormone-binding globulin (SHBG), and disrupted follicular development. These processes reinforce one another, linking metabolic dysfunction with hyperandrogenism and ovulatory abnormalities.
Diabetes and metabolic complications
A pooled analysis of 41 studies reported increased odds of impaired fasting glucose (OR 3.2), impaired glucose tolerance (OR 3.9), and type 2 diabetes (OR 2.9) in women with PMOS. Importantly, the increased diabetes risk is also observed in women without obesity. The review highlights the importance of regular glycemic surveillance. The 2023 International Evidence-Based Guideline recommends testing at least every 3 years, with more frequent assessment for women with additional risk factors, including previous gestational diabetes, family history of type 2 diabetes and elevated BMI. A 75-g oral glucose tolerance test is identified as the preferred assessment method, although practical limitations affect its accessibility. Metabolic dysfunction-associated steatotic liver disease (MASLD) is another important complication. A pooled prevalence of 43% has been reported among women with PMOS, with insulin resistance, metabolic syndrome and biochemical hyperandrogenism identified as associated risk factors.
Cardiovascular risk
The review presents evidence that cardiovascular complications emerge earlier in women with PMOS than in the general female population. The condition is associated with a 20%–70% increased risk of cardiovascular disease, depending on the population studied, and an approximately 3-fold increased risk of type 2 diabetes.
Atherogenic dyslipidemia affects 60%–70% of women with PMOS, typically involving elevated triglycerides, reduced HDL cholesterol and increased small dense LDL particles. Hypertension occurs 2–3-fold more frequently than in age-matched controls. Central obesity, chronic inflammation and endothelial dysfunction further contribute to cardiovascular risk. Population-based studies provide evidence of increased cardiovascular events, not merely an unfavourable risk-factor profile. A Danish cohort comparing 18,112 women with PMOS with 54,336 matched controls reported an increased incidence of cardiovascular disease (HR 1.71; 95% CI, 1.56–1.88). Risks were also elevated for myocardial infarction (HR 1.78) and ischemic heart disease (HR 1.73).
A Nordic population-based cohort of nearly 130,000 women reported an increased risk of cardiovascular disease (HR 1.27 [1.18; 1.36]), major adverse cardiovascular events (1.21 [1.10; 1.34]) and deep venous thrombosis (1.30 [1.27; 1.33]). Cardiovascular risk was also elevated among women with a BMI below 25 kg/m² (HR 1.40 [1.26; 1.55]). Notably, cardiovascular risk curves began to diverge at approximately 35 years of age in population-based studies, emphasizing the importance of early identification and preventive care.
Management and emerging treatment approaches
Lifestyle intervention, including structured exercise, balanced nutrition and behavioural strategies, remains the foundation of management. Metformin is recommended particularly for adults with a BMI of 25 kg/m² or higher, with benefits for insulin sensitivity and glycemic outcomes. GLP-1 receptor agonists may provide greater weight reduction than metformin, although evidence specifically in PMOS remains limited. A systematic review of 11 randomized controlled trials reported a reduction in BMI of 1.38 kg/m² (95% CI 0.38–2.39 kg/m²). These medications are contraindicated during pregnancy, and effective contraception is recommended during treatment. For severe obesity, bariatric surgery may improve weight, diabetes, hypertension, ovulation and fertility. Treatment decisions should be individualized according to metabolic risk, clinical manifestations and reproductive goals.
The review reinforces PMOS as a lifelong multisystem endocrine and metabolic disorder rather than an isolated reproductive condition. Insulin resistance and compensatory hyperinsulinemia provide an important biological link between reproductive dysfunction, type 2 diabetes and cardiovascular disease. Population-based evidence indicates that cardiovascular risk may emerge from early adulthood, including in women without obesity. The authors emphasize early diagnosis, systematic metabolic surveillance, cardiovascular risk assessment and individualized interventions as priorities for improving long-term outcomes.
The article is a review of evolving evidence, not a new clinical trial. Several therapeutic approaches remain supported by limited or low-quality evidence, and further research is needed to develop validated cardiovascular risk-prediction tools and long-term prevention strategies.
Copyright © Skyscape. All rights reserved.
Source: Forslund, M., Melin, J., Joham, A.E., et al. Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk. Journal of Internal Medicine. 2026; Published: August 30, 2026. DOI: 10.1111/joim.70156.
KEY FINDINGS: EchoNet-AS integrates structural and functional echocardiographic information to provide automated assessment of AS severity. Its strong performance across geographically distinct and temporally separate cohorts supports the potential generalizability of this approach. The findings suggest that multiview deep learning could support clinicians in identifying severe AS and interpreting complex echocardiographic findings. However, the model is intended as a potential clinical decision-support tool rather than a replacement for comprehensive echocardiographic assessment. Prospective evaluation in routine clinical workflows is necessary to establish its effect on diagnostic decisions and patient outcomes.
BACKGROUND: Accurate assessment of aortic stenosis (AS) severity requires integration of structural valve abnormalities with functional measurements, including transvalvular blood flow velocities and pressure gradients. Conventional echocardiographic assessment relies on combining visual interpretation with quantitative Doppler measurements, which may be challenging when findings are discordant or imaging quality is suboptimal. Artificial intelligence models that analyze either structural or functional information independently may not capture the full spectrum of AS severity. This study developed and validated EchoNet-AS, a deep learning framework designed to integrate multiple echocardiographic views with Doppler measurements to improve automated AS assessment.
DETAILS: This multicenter retrospective validation study used transthoracic echocardiography data from Kaiser Permanente Northern California (KPNC), Stanford Healthcare (SHC), and Cedars-Sinai Medical Center (CSMC). The investigators developed EchoNet-AS, an open-source framework combining video-based convolutional neural networks to assess aortic valve motion with segmentation models to automate measurement of peak aortic valve velocity and classify AS severity. The model was trained using 210,193 images from 16,076 echocardiographic studies at KPNC. Validation included 1,588 held-out studies, a temporally distinct cohort of 19,202 studies, and external cohorts comprising 2,415 studies from SHC and 9,038 studies from CSMC. The primary objective was to evaluate the model's ability to distinguish severe AS by integrating information from multiple echocardiographic videos and Doppler measurements. EchoNet-AS demonstrated high diagnostic discrimination for severe AS across the evaluated cohorts. The area under the receiver-operating characteristic curve (AUROC) was 0.964 (95% CI: 0.952-0.973) in the KPNC held-out cohort and 0.986 (0.983-0.989) in the temporally distinct cohort. External validation demonstrated similarly strong performance, with an AUROC of 0.985 (0.975-0.992) at SHC and 0.989 (0.986-0.992) at CSMC. The integrated multiview approach outperformed models relying on individual echocardiographic views or Doppler measurements alone.
KEY FINDINGS: Implementation of a higher-dose oxytocin protocol during the third stage of labor was associated with a reduction in overall PPH, primarily driven by improved outcomes following vaginal delivery. The findings suggest that modifying oxytocin administration may represent a potentially useful approach to postpartum hemorrhage prevention. However, the study's single-center, before-and-after design limits causal interpretation. The findings do not establish the optimal oxytocin dose or demonstrate that the protocol is appropriate for all delivery settings. Further research is needed to assess safety, effectiveness across delivery modes, and reproducibility in other clinical settings.
BACKGROUND: Postpartum hemorrhage (PPH) remains a major cause of maternal morbidity and mortality. Oxytocin is routinely administered after childbirth to promote uterine contraction and prevent excessive bleeding. However, the optimal prophylactic dose and administration protocol remain uncertain. A quality-improvement study conducted at a high-volume academic medical center evaluated whether increasing the oxytocin dose administered during the third stage of labor was associated with reduced postpartum blood loss and hemorrhage.
DETAILS: The single-center quality-improvement study compared maternal outcomes before and after implementation of a high-dose oxytocin protocol at the University of Michigan Health Von Voigtlander Women's Hospital. The analysis included 2,674 births between January 1 and July 6, 2024, comprising 1,309 births before and 1,365 births after protocol implementation. The standard protocol administered 30 units of oxytocin over 1 hour, followed by 3.6 units over an additional hour. The revised protocol administered 60 units over 1 hour during the third stage of labor. Implementation involved modifications to medication orders and infusion pumps, along with staff education and training. The primary outcome was PPH, defined as quantitatively measured blood loss of 1,000 mL or greater. Secondary outcomes included quantitative blood loss, with additional analyses stratified by delivery mode. Postpartum hemorrhage occurred in 14.3% of births before implementation and 11.2% afterward (adjusted relative risk [aRR], 0.77; 95% CI, 0.64-0.93). Median quantitative blood loss decreased from 444 mL (IQR, 240-749 mL) to 396 mL (IQR, 200-673 mL), with an adjusted median difference of -43 mL (95% CI, -72 to -14 mL). Among vaginal births, PPH rates decreased from 8.5% to 5.2% (aRR, 0.60; 95% CI, 0.42-0.86). Median blood loss declined from 317 mL (IQR, 153-545 mL) to 266 mL (IQR, 147-480 mL), with an adjusted median difference of -33 mL (95% CI, -65 to -1 mL). Among cesarean births, PPH occurred in 23.4% before implementation and 21.8% afterward (aRR, 0.89; 95% CI, 0.71-1.11), indicating no statistically significant reduction.
KEY FINDINGS: The outbreak is caused by Bundibugyo virus, a distinct Ebola virus species for which no licensed vaccine or specific treatment is currently available. This limits the availability of virus-specific medical countermeasures and reinforces the importance of early diagnosis, supportive clinical care, and rigorous infection prevention and control.
Healthcare facilities should maintain heightened awareness of compatible illness in patients with relevant travel or exposure histories. Prompt identification, appropriate isolation, laboratory testing, contact tracing, and coordinated public health response remain critical to reducing transmission. ECDC continues to monitor the outbreak and provide epidemiological updates and risk assessments.
BACKGROUND: An outbreak of Ebola disease caused by Bundibugyo virus (BDBV) has been ongoing in the Democratic Republic of the Congo (DRC) since May 2026. The outbreak has expanded beyond the DRC, with imported cases reported in Kenya and Nigeria during October. The emergence of cases across multiple countries underscores the importance of early case recognition, cross-border surveillance, infection prevention and control (IPC), and coordinated public health preparedness.
DETAILS: According to the European Centre for Disease Prevention and Control (ECDC), as of 29 October 2026, the DRC had reported 10,274 confirmed cases and 4,992 related deaths, based on data through 28 October. Community transmission continues across eight provinces. Kenya reported nine confirmed cases, including two deaths, as of 26 October. All cases were epidemiologically linked to the initial imported case, with no evidence of wider community transmission reported in the available assessment. The second death was reported on 23 October in a patient who was the third confirmed case in the Kenyan cluster.
Nigeria reported an Ebola case on 20 October in an individual with a travel history to Uganda. The patient was subsequently medically evacuated to Switzerland. As of 29 October, 62 contacts had been identified and were under follow-up. Epidemiological investigations and contact tracing remain ongoing.
The outbreak continues to pose a substantial public health challenge, particularly in the DRC, where sustained community transmission and high mortality have been reported. The expansion into Kenya and Nigeria highlights the potential for international spread through population movement and travel.
In Kenya, the identification of nine cases, including two deaths, within a single epidemiologically linked cluster suggests that contact tracing and isolation have been central to containing transmission. However, the continued occurrence of cases requires sustained monitoring. ECDC emphasizes that the outbreak may be larger than currently reported because of gaps in epidemiological information and incomplete contact follow-up.
Copyright © Skyscape. All rights reserved.
Source: European Centre for Disease Prevention and Control (ECDC). Ebola disease: Multi-country outbreak 2026. ECDC. 2026; Published: October 30, 2026.
KEY FINDINGS: HFpEF and CKD should be considered interconnected conditions rather than isolated disorders. Traditional cardiovascular risk factors and CKD-specific pathophysiological processes contribute to heart failure risk, while the heterogeneity of HFpEF complicates clinical assessment. Phenotype-informed risk stratification may help clinicians identify high-risk patients and tailor preventive care. The review emphasizes the need to integrate kidney disease assessment into cardiovascular risk evaluation and prevention planning. s
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) frequently coexist and contribute to substantial morbidity and mortality. In patients with CKD, traditional cardiovascular risk factors combine with kidney-specific pathophysiological mechanisms to increase susceptibility to HFpEF. The clinical heterogeneity of HFpEF complicates diagnosis, risk stratification, prevention, and treatment, highlighting the need for approaches that account for the interaction between cardiac and renal disease.
DETAILS: In this Kidney Cross-Talk review, Krishnan and colleagues examine the epidemiology of HFpEF in patients with CKD, the mechanisms linking kidney dysfunction to HFpEF development, and the influence of CKD on HFpEF phenotyping. The authors discuss how identifying distinct clinical phenotypes may improve characterization of disease, support individualized management, and strengthen risk prediction. They also propose a risk-based algorithm for preventing heart failure in patients with CKD.
This is a narrative review rather than a clinical trial or meta-analysis; therefore, it does not report a single pooled treatment effect. The authors highlight the contribution of CKD-related mechanisms to HFpEF development and the importance of recognizing distinct HFpEF phenotypes to improve risk assessment and guide preventive strategies. The proposed risk-based prevention algorithm offers a framework for identifying patients with CKD who may benefit from more targeted heart failure prevention.
Copyright © Skyscape. All rights reserved.
Source: Krishnan, V., Khan, S. S., and Mehta, R. The Intersection of Heart Failure with Preserved Ejection Fraction and CKD. Clinical Journal of the American Society of Nephrology. 2026; 21(10): 1847-1855. Published: October 22, 2026. DOI: 10.2215/CJN.0000001013.
Specialty: